Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that ILC1-like cells can induce alopecia areata in healthy human hair follicles, challenging the traditional belief that the disease is primarily driven by CD8+ T cells.

This case report describes a 42-year-old Indian female with acute diffuse and total alopecia who experienced sudden diffuse hair loss within one day, differentiating it from telogen effluvium through specific dermoscopic findings.

This study found that modeling and simulation effectively informed decision-making and dose selection for ritlecitinib in treating alopecia areata, supporting an accelerated drug development strategy.

This study investigated vitamin D receptor expression in normal hair follicles and those affected by alopecia areata, focusing on various markers using immunohistochemical staining.

In this case report, a 37-year-old patient with APECED showed significant clinical improvement, including hair regrowth and resolution of skin issues, after 11 months of treatment with ruxolitinib, highlighting the potential of JAK inhibitors in managing this complex autoimmune disease.

This case study suggests that autoimmunity involving cytotoxic CD8+ T cells may link alopecia areata and human T-cell lymphotropic virus-1-associated myelopathy in adult T-cell leukemia/lymphoma patients.

Deuruxolitinib is generally safe for treating alopecia areata.

This review reports no new results and highlights existing research suggesting JAK inhibitors may be effective in treating inflammatory skin conditions like alopecia areata, atopic dermatitis, psoriasis, and vitiligo.

This review discusses the causes and diagnosis of traction alopecia, emphasizing education for high-risk populations as there is currently no cure, and presents no new clinical findings.

This study reported that most patients with alopecia areata who responded to ritlecitinib treatment by achieving a SALT score ≤20, SALT score ≤10, or improvements in eyebrow and eyelash assessments at Week 24 maintained their responses through Week 48.

This report describes the co-occurrence of vitiligo and alopecia areata in pediatric cases but provides no new clinical findings.

This case report discusses a successful treatment of Alopecia Areata with tofacitinib and includes a literature review on the condition's pathophysiology and the mechanism of JAK inhibitors, though it notes the high failure rate of available treatments and absence of FDA-approved options.

In this study on mice, a baricitinib-loaded microneedle patch enhanced hair growth in alopecia areata lesions (68% vs control: 33%, p < 0.05), suggesting it may deliver treatment effectively and pain-free, with fewer systemic side effects.

This paper highlights that traction alopecia is common among certain ethnic groups and occupations due to tight hairstyling practices, but early-stage hair loss can often be reversed with treatment and by avoiding these styling habits, as observed in Hispanic and Black women.

In this study, baricitinib showed promising results in improving scalp, eyebrow, and eyelash hair loss in adults with severe and very severe alopecia areata over 52 weeks.

This handbook of dermatology provides a comprehensive practical manual for dermatologists, but reports no new research findings.

In this quasi-experimental study, 24-week tofacitinib treatment significantly improved hair regrowth in South Asian patients with alopecia areata, but a high relapse rate post-withdrawal signals the need for continuous treatment strategies.

In this six-year study of a Saudi cohort, oral tofacitinib showed favorable long-term effectiveness for patients with AA, with manageable adverse events requiring regular monitoring.

This study found that oral tofacitinib monotherapy improved nail changes in 73.3% of adults with moderate-to-severe alopecia areata over a median period of 5 months, but nail improvement was not linked to the severity of hair loss or hair regrowth.

This report describes a case of alopecia areata incognita in a 6-year-old child, marked by sudden diffuse hair loss without bald patches, typically observed in adults.

In this study, a patient with recalcitrant lichen planopilaris and frontal fibrosing alopecia showed significant improvement after receiving four doses of the interleukin-23 monoclonal antibody tildrakizumab.

In this case report, a 24-year-old male with alopecia areata showed significant hair regrowth and symptom improvement after 45 days of a comprehensive Ayurvedic treatment, with sustained results at a 60-day follow-up.

This study found that increased Bcl-2 protein expression after DPCP treatment was associated with hair regrowth in alopecia areata patients, suggesting its role in inhibiting apoptosis.

This study reports a strong association between the MICA locus, specifically the MICA∗3-DR∗6-DQ6 haplotype, and Alopecia Areata in families.

In this study, carbon dots derived from dandelion herb demonstrated significant antibacterial and biofilm-disrupting capabilities, promoting wound healing in a mouse model infected with S. aureus, while also showing excellent biocompatibility and the ability to modulate reactive oxygen species.

This study found that the novel drug VDC-1101 showed a 45% objective response rate in treating canine cutaneous T-cell lymphoma, offering a potential treatment option for this challenging disease.

This study reports a notable case of a patient with psoriatic arthritis and alopecia universalis who experienced significant improvement in both conditions after treatment with the JAK1 selective inhibitor upadacitinib, suggesting its potential efficacy for alopecia universalis, especially in cases involving inflammatory arthritis.

This text is a website user interface and does not include an abstract summary or research findings.

This study found that postnatal treatment with recombinant EDA normalized adult teeth, improved sweating, and restored normal lacrimation in dogs with XLHED, suggesting its potential as a treatment for the condition.